Merck dissolves Simcere JV amid rapid China changes
This article was originally published in Scrip
Executive Summary
Once hailed as the model for global going local in China, a joint venture created merely three years ago between Merck and Simcere has quietly faded into history. Does the move signal that the JV model is not working in China?
You may also be interested in...
Can An Elephant Crack China’s Bamboo Ceiling For Generics?
Among the many challenges facing foreign generics firms operating in China, dealing with ever-tightening policies and regulations is probably the toughest, and has already forced several multinationals to quit the market. But one Indian joint venture is looking to effectively exploit targeted niche opportunities.
Can An Elephant Crack China’s Bamboo Ceiling For Generics?
Among the many challenges facing foreign generics firms operating in China, dealing with ever-tightening policies and regulations is probably the toughest, and has already forced several multinationals to quit the market. But one Indian joint venture is looking to effectively exploit targeted niche opportunities.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.